Drugs in Dev. Infections and Infectious Diseases
Undisclosed
Italy 
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A patent on the use of raloxifene for the treatment of people affected by COVID-19 was filed by Dompé farmaceutici, Fraunhofer Institute and Leuven University to promote universal access to related therapies that may be developed, in line with Exscalate...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Malaria Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : The EU Malaria Fund
Deal Size : Undisclosed
Deal Type : Funding
Details : The investment supports development of a novel Malaria vaccine on Achilles versatile technology platform to produce low-cost, safe and self-adjuvanting fit-for-purpose vaccines. To also supports produce low-cost, safe and self-adjuvanting fit-for-purpose...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 19, 2020
Lead Product(s) : Malaria Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : The EU Malaria Fund
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Adenoviral Vector-Based Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Univercells
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The pan-European consortium of ReiThera, LEUKOCARE and Univercells brings together an adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 23, 2020
Lead Product(s) : Adenoviral Vector-Based Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Univercells
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Linear DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The vaccine is one of four PCR-produced (polymerase chain reaction vaccine) linear DNA vaccine candidates under joint development by Takis Biotech and Applied DNA.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 18, 2020
Lead Product(s) : Linear DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
